Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results in Africa
A long-acting injectable drug, lenacapavir, administered just twice a year, continues to demonstrate strong protection against HIV infection in ongoing studies across Africa, according to recent reports. The development marks a significant step forward in the global effort to expand prevention options for populations at risk of contracting the virus. A New Approach to HIV […]
Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results in Africa Read More »